Rentschler Biopharma to build cell and gene therapy manufacturing capabilities in the UK
Rentschler Biopharma, a German contract development and manufacturing organisation (CDMO), will build new cell and gene therapy capabilities at a Cell and Gene Therapy (CGT) Catapult site in Stevenage, UK.
As part of the agreement, Rentschler will invest in the site over the next five years to bolster their manufacturing capabilities.
This investment is expected to make a ‘major contribution’ to creating suitable manufacturing capability for cell and gene therapies, the CGT Catapult said in a statement.
The German company will establish manufacturing capability in advanced therapy medicinal products (ATMPs), including adeno-associated virus (AAV) Vectors for clinical trial supply.
Read more: http://www.pharmatimes.com/news/rentschler_biopharma_to_build_cell_and_gene_therapy_manufacturing_capabilities_in_the_uk_1363141
As part of the agreement, Rentschler will invest in the site over the next five years to bolster their manufacturing capabilities.
This investment is expected to make a ‘major contribution’ to creating suitable manufacturing capability for cell and gene therapies, the CGT Catapult said in a statement.
The German company will establish manufacturing capability in advanced therapy medicinal products (ATMPs), including adeno-associated virus (AAV) Vectors for clinical trial supply.
Read more: http://www.pharmatimes.com/news/rentschler_biopharma_to_build_cell_and_gene_therapy_manufacturing_capabilities_in_the_uk_1363141
